Comparative Pharmacology
Head-to-head clinical analysis: LERITINE versus NUMORPHAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LERITINE versus NUMORPHAN.
LERITINE vs NUMORPHAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LERITINE (anileridine) is a synthetic opioid analgesic that acts as a mu-opioid receptor agonist, modulating pain perception and emotional response to pain.
Opioid agonist; binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception.
Adults: 25-50 mg orally every 6 hours as needed for pain; not to exceed 200 mg/day.
Intravenous or subcutaneous: 0.5-2 mg (0.1-0.2 mg/kg for severe pain) every 2-3 hours as needed; not to exceed 20 mg/day.
None Documented
None Documented
2-3 hours (terminal half-life in adults; may be prolonged in hepatic impairment or elderly, dosing adjustments recommended)
Terminal elimination half-life is 2–3 hours in adults; prolonged to 3–4 hours in elderly and up to 15 hours in patients with severe hepatic impairment.
Renal (70-90% as unchanged drug and metabolites); biliary/fecal (10-30%)
Primarily renal (approximately 70% as unchanged drug, <5% as noroxymorphone and other conjugates); biliary/fecal excretion accounts for ~20%.
Category C
Category C
Opioid Analgesic
Opioid Analgesic